Rheumatoid Arthritis Stem Cell Therapy Market Report 2021 by Global Key Players, Types, Applications, Countries, Size, Forecast to 2027 Clark County…

The recent report on Rheumatoid Arthritis Stem Cell Therapy Market Report 2021 by Key Players, Types, Applications, Countries, Market Size, forecast to 2027 offered by Credible Markets, comprises of a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. Additionally, the report also highlights the challenges impeding market growth and expansion strategies employed by leading companies in the Rheumatoid Arthritis Stem Cell Therapy Market.

An exhaustive competition analysis that covers insightful data on industry leaders is intended to help potential market entrants and existing players in competition with the right direction to arrive at their decisions. Market structure analysis discusses in detail Rheumatoid Arthritis Stem Cell Therapy companies with their profiles, revenue shares in market, comprehensive portfolio of their offerings, networking and distribution strategies, regional market footprints, and much more.

Request for Sample with Complete TOC and Figures & Graphs @ https://www.crediblemarkets.com/sample-request/rheumatoid-arthritis-stem-cell-therapy-market-327877?utm_source=Komal&utm_medium=SatPR

Rheumatoid Arthritis Stem Cell Therapy market is segmentedBy Company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Rheumatoid Arthritis Stem Cell Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type

Allogeneic Mesenchymal Stem Cells

Bone Marrow Transplant

Adipose Tissue Stem Cells

Segment by Application

Hospitals

Ambulatory Surgical Centers

Specialty Clinics

By Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

By Company

Mesoblast

Roslin Cells

Regeneus

ReNeuron Group

International Stem Cell Corporation

Regional Analysis of Global Rheumatoid Arthritis Stem Cell Therapy Market

All the regional segmentation has been studied based on recent and future trends, and the market is forecasted throughout the prediction period. The countries covered in the regional analysis of the Rheumatoid Arthritis Stem Cell Therapy market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Russia, Italy, Spain, Turkey, Netherlands, Switzerland, Belgium, and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and Argentina, Brazil, and Rest of South America as part of South America.

Direct Purchase this Market Research Report Now @ https://www.crediblemarkets.com/reports/purchase/rheumatoid-arthritis-stem-cell-therapy-market-327877?license_type=single_user;utm_source=Komal&utm_medium=SatPR

What does the Report Include?

The market report includes a detailed assessment of various drivers and restraints, opportunities, and challenges that the market will face during the projected horizon. Additionally, the report provides comprehensive insights into the regional developments of the market, affecting its growth during the forecast period. It includes information sourced from the advice of expert professionals from the industry by our research analysts using several research methodologies. The competitive landscape offers further detailed insights into strategies such as product launches, partnership, merger and acquisition, and collaborations adopted by the companies to maintain market stronghold between 2021 and 2027.

The report can answer the following questions:

North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Rheumatoid Arthritis Stem Cell Therapy industry.

Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Rheumatoid Arthritis Stem Cell Therapy industry.

Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Rheumatoid Arthritis Stem Cell Therapy industry.

Different types and applications of Rheumatoid Arthritis Stem Cell Therapy industry, market share of each type and application by revenue.

Global market size (sales, revenue) forecast by regions and countries from 2021 to 2027 of Rheumatoid Arthritis Stem Cell Therapy industry.

Upstream raw materials and manufacturing equipment, industry chain analysis of Rheumatoid Arthritis Stem Cell Therapy industry.

SWOT analysis of Rheumatoid Arthritis Stem Cell Therapy industry.

New Project Investment Feasibility Analysis of Rheumatoid Arthritis Stem Cell Therapy industry.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.crediblemarkets.com/enquire-request/rheumatoid-arthritis-stem-cell-therapy-market-327877?utm_source=Komal&utm_medium=SatPR

Contact Us

Credible Markets Analytics 99 Wall Street 2124 New York, NY 10005 Email:[emailprotected]Follow Us:LinkedIn|Twitter|Facebook

https://clarkcountyblog.com/

The rest is here:
Rheumatoid Arthritis Stem Cell Therapy Market Report 2021 by Global Key Players, Types, Applications, Countries, Size, Forecast to 2027 Clark County...

CRISPRoff Reversible Epigenome Editing Method Could Enable Safer, More Precise Therapeutics – GenomeWeb

NEW YORK As CRISPR researchers develop new and better ways to edit the genome while leaving as few unintended consequences as possible behind, a team led by scientists at the University of California, San Francisco and MIT has developed a method that would create completely reversible gene edits.

In a recent study in Cell, UCSF's Luke Gilbert, MIT's Jonathan Weissman, and their colleagues described their method, called CRISPRoff a programmable epigenome editor consisting of a single dead Cas9 fusion protein that establishes DNA methylation and repressive histone modifications. This transient CRISPRoff expression initiates highly specific repression of genes and DNA methylation that's maintained through cell division and differentiation of stem cells to neurons. In their experiments, they found that the epigenome editing was highly specific, with minimal off-target editing.

In order to reverse this effect, the researchers then engineered a switch they called CRISPRon, through which they used Cas9-mediated gene editing to inactivate DNMT1 the main DNA methylation maintenance enzyme in mammalian cells in cells where they had previously silenced specific genes. Post-DNMT1 knockout, 60 percent to 80 percent of cells demonstrated reactivated gene expression. Similarly, treatment of cells with a small-molecule inhibitor of DNMT1 showed reactivated expression of genes that had previously been silenced, demonstrating that depletion of DNA methylation was sufficient to reverse CRISPRoff-mediated gene silencing.

"If you want to fix a pathogenic mutation, then CRISPR is really enabling. But we felt that for many applications, you may not want to permanently mutate the genome," Gilbert said, explaining the method's genesis. "So, we were searching for ways to turn gene expression off or on, without manipulating the sequence of the genome and just manipulating the transcripts that are produced by a cell."

Medically, he noted, there could be many applications where patients might feel more comfortable with using genome editing if they know that their genes won't be permanently changed, in part based on the concept that gene therapy has already been in use for a variety of applications for more than a decade.

Gilbert further noted that while he, Weissman, and many other CRISPR researchers have been working with tools such as CRISPR interference (CRISPRi) that can downregulate gene expression rather than turning it off entirely, these tools are more awkward to work with from a therapeutic standpoint. While a regular CRISPR-Cas system uses a Cas nuclease to latch onto a gene a mutate it in some fashion to turn it off, CRISPRi uses deactivated Cas9, resulting in RNA-directed transcriptional control of the target region. In other words, it functions "almost like normal transcription factors within a cell, where you constitutively express proteins to target the gene, and then that turns the gene on or off," Gilbert explained. "One of the advantages of Cas9 is you can express it briefly and it'll make a change to the genome that's permanent, and carry it out for a long time. We were looking for ways to basically leverage the strengths of Cas9's permanence and durability, but also leverage this epigenetic editing feature of not having to permanently mutate a gene."

The dead Cas9 works as a programmable DNA binding element rather than as a programmable nuclease, Weissman added.

In terms of therapeutic applications for human beings, the technology has a lot of possible uses, the researchers believe. Before there was an Ebola vaccine, for example, they were working on CRISPRoff as a way to confer programable immunity for anyone who might be affected by the disease.

"If you have a virus where you know the receptor, you could use CRISPRoff to turn gene expression off," Gilbert said. For Ebola that receptor is a protein called NPC1. "We know if you turn NPC1 off in the liver, you're immune to Ebola. But you don't want to permanently mutate NPC1 because you cause cholesterol processing defects and lysosomal storage disorder phenotypes," he added. The idea they had, therefore, was to deliver CRISPRoff to the liver of healthcare workers traveling to Ebola hotspots so that they'd be completely immune to the disease while working with patients.

"And when they left the Ebola hotspot, to avoid detrimental effects of mutating or permanently silencing NPC1, then you could redeliver CRISPRon to restore gene expression and therefore not have any detrimental phenotypes from permanently losing that gene function," Gilbert added.

He further noted that the technology could even be used to modulate pain response. If someone were planning to have surgery, or recovering from an injury, CRISPRoff could be administered to shut down pain receptors for a short time. Once the patient recovered, the pain receptors could be turned back on. It would also help people avoid opioid pain killers.

Another example, according to Weissman, would be in the area of oncology. Cancer studies often reveal the presence of genes or gene mutations that lead to resistance to chemotherapy or radiotherapy. CRISPR is now being considered as a possible addition to some late-stage cancer patients' therapies as a way to knock out resistance genes and reawaken therapeutic response.

In May 2019, Christiana Care's Health System's Gene Editing Institute was preparing to file an investigational new drug application with the US Food and Drug Administration for a clinical trial protocol that would use CRISPR genome editing to improve the efficacy of chemotherapy for KRAS-positive non-small-cell lung cancer (NSCLC) patients. The protocol involved using CRISPR-Cas9 gene editing to knock down NRF2 in order to render patients more sensitive to chemotherapeutic agents.

Under a scenario using CRISPRoff, that gene's expression may only be off for the time it takes to administer the necessary cancer treatment. "You can imagine turning on or off genes in your intestine or in your blood stem cells," Weissman said. "The cells are more sensitive to radiation. But then after you have the radiotherapy, [the cells could return] to normal states so you don't have to worry about the long-term consequences of turning off the gene."

Weissman noted there may be some instances where CRISPRon isn't needed to turn gene expression back on. While conducting their experiments, the researchers noted that the gene silencing in certain loci would decay over a period of days or weeks, depending on the cell cycle turnover rate.

"If that can be tuned, we can now come in [with] one type of treatment and over the period of, say, weeks or months, it would naturally restore and you don't have to come in with the second," Weissman said.

That rate of decay would depend on the tissue in question and the dynamics of tissue turnover "will dictate how long these program changes last," Gilbert added. "In post-mitotic cells like muscle or neuron, these methyl marks in non-replicating cells may last for years and years. So, it depends on the cell type."

There are still many elements to CRISPRoff that have to be worked out and refined before it can be used in the clinic. As with any CRISPR system meant to be used as a therapy, delivery into the right cells at the right time is currently the principal challenge, Gilbert said. The researchers are also working on making the CRISPRoff complex smaller, and capable of targeting more than one loci at once, Weissman added.

But there's already been clear interest in commercializing the technology, he said. Both he and Gilbert, as well as a few other researchers who authored the paper, have already filed for patents on CRISPRoff and CRISPRon.

Indeed, Weissman said, the technology could have applications in cell therapy, and could even aid in the development of so-called off-the-shelf allogeneic CAR-T cells. The current procedure for making CAR Ts is expensive and time-consuming because it involves harvesting an individual's cells, engineering them, and re-administering them as a treatment. As of now, allogeneic CAR Ts could cause life-threatening graft-versus-host disease, and could be rejected by the host immune system.

Using CRISPRoff, however, Weissman envisions being able to edit allogeneic CAR Ts in ways that would camouflage them from an individual's immune system, while also adding safety controls that would allow a physician to turn the CAR Ts off, if needed. "It could make it a much more accessible treatment," he said. "You could have a safer and more universal cell therapy, and you can then do much more complicated engineering because you only have to do it once for many patients, as opposed to trying to do this complicated engineering in a bespoke way for each patient."

Overall, he added, what the study really shows is that cutting DNA and then repairing it is quite difficult. And while researchers have gotten better at avoiding off-target effects, so-called on-target off-targets unintended consequences of on-targets editing such as DNA damage response, large indels, and even chromothripsis, can still do damage to the genome.

"So, when you don't have to do that, therapeutically, there are lot of advantages," Weissman said. "Things like base editor and prime editor are examples of this, and we see CRISPRoff as a complement to this, which allows you to do epigenome editing from beginning to end, and to do it in a clean and controlled way."

See the article here:
CRISPRoff Reversible Epigenome Editing Method Could Enable Safer, More Precise Therapeutics - GenomeWeb

Cell Therapy Market To Expand At An expeditious Growth Rate From 2021-2027 | Thermo Fisher Scientific, Nanofiber Solutions, Advanced Biomatrix,…

Adroit Market Research has added a detailed study on the Cell Therapy market which provides a brief summary of the growth trends influencing the market. The global Cell Therapy market study offers a thorough examination of economic growth, technical advances, and a practical evaluation of technology suppliers. In the global Cell Therapy market analysis, on-demand triggers, vulnerabilities, and other factors such as fluctuating production rates, R&D spending, and organizational difficulties are all clear.

The report delivers detailed market segmentation, such as shape, functionality, and geographic regions, is a major focus of global Cell Therapy market research.

Request for Free Sample Research Report on Cell Therapy Market @ https://www.adroitmarketresearch.com/contacts/request-sample/611?utm_source=AD

(The free sample report is updated with new research additions and quickly available on request).

The annual Cell Therapy market report looks at a variety of tactics used by leading service companies, such as mergers and acquisitions, alliances, deals, and other approaches. Market size, market growth factors, and market segmentation are all examined in detail in the Cell Therapy market research report.

The factors that have fueled and hampered the development of the Cell Therapy industry are also examined in this market research study. The global business analysis provides key perspectives on core developed economies and developing markets, depending on the regional development of the Cell Therapy market. The industrys national and regional breakdowns, growth size, as well as its dynamics, consumer positions, trends and policies, industry segmentation, and the ever-shifting global market condition, are all examined in the Cell Therapy industry review. The research overview also traces the previous industrys Cell Therapy as well as the global markets projected value dependent on geographic analysis.

Cell Therapy Market by leading Manufacturers (2021-2026):

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost

Browse complete report with in-depth TOC @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market?utm_source=AD

The global Cell Therapy industry research study compares economies and national demographics in order to understand the significance of the Cell Therapy sector in a changing regional scenario. The global Cell Therapy industry report also looks at the number of technological advancements that have arisen in recent years, as well as how quickly they have been embraced. The aim analysis report also includes a concise market segmentation environment and a diagram of the Cell Therapy industrys regional scenario. This study also covers the type, implementation, end-user industry, and regions, which include Europe, North America, Asia Pacific, MEA, and the Rest of the World.

Global Cell Therapy Market Trends: By Product

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

Major Reasons to purchase this Report:

The global Cell Therapy report also provides an extensive study of the strategies adopted by new and prominent service providers.

This study goes into great detail about competitive opportunities, driving forces, market limitations, and research and development.

It covers technological developments, growth potential, key trends, and market dynamics.

In terms of the geographic perspective, the Cell Therapy market research report delivers concise research of

Key perspectives across a range of technologies and applications markets.

Major Points Covered in TOC:

Overview: Along with a broad overview of the Cell Therapy market, this section gives an overview of the report to give an idea about the nature and contents of the research study.

Analysis on Strategies of Leading Players: Market players can use this analysis to gain a competitive advantage over their competitors in the Cell Therapy market.

Study on Key Market Trends: This section of the report offers a deeper analysis of the latest and future trends of the Cell Therapy market.

Market Forecasts: Buyers of the report will have access to accurate and validated estimates of the total market size in terms of value and volume. The report also provides consumption, production, sales, and other forecasts for the Cell Therapy market.

Regional Growth Analysis: All major regions and countries have been covered in the report. The regional analysis will help market players to tap into unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets.

Segmental Analysis: The report provides accurate and reliable forecasts of the market share of important segments of the Cell Therapy market. Market participants can use this analysis to make strategic investments in key growth pockets of the Cell Therapy market.

You can also get individual chapter wise section or region wise report versions like North America, Europe or Asia or Country like US, UK, China and other.

Inquire more before buying this report Here @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611?utm_source=AD

About Us :

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX75204, U.S.A. Phone No.: USA: +1 972-362 -8199/ +91 9665341414

View post:
Cell Therapy Market To Expand At An expeditious Growth Rate From 2021-2027 | Thermo Fisher Scientific, Nanofiber Solutions, Advanced Biomatrix,...

FTC continues to crack down on companies peddling fake COVID treatments and cures – HamletHub

As part of our ongoing efforts to protect you from sellers of scam COVID-19 treatments, the FTC has sent 30 warning letters to companies that claimed their products can prevent, treat, or cure COVID-19. These letters gave the sellers 48 hours to notify the FTC of the specific actions they have taken to address the agencys concerns. Companies failing to make adequate corrections could have faced lawsuits under the 2020 COVID-19 Consumer Protection Act. Not only does the law make it illegal to deceptively market products that claim to prevent, treat, or cure COVID-19, it also lets the FTC seek financial penalties. The good news: as a result of these letters, all the companies have stopped making the false or deceptive claims.

The companies involved peddle everything from chiropractic adjustments, exercise sessions, nasal mists and rinses, vitamins, supplements, and extracts. Theres a slew of therapies with impressive names like peptide, oxidative, stem cell, ozone, intravenous vitamin, and infrared sauna therapy. All of these products and treatments have one thing in common: there is no evidence as required by law that they work against the Coronavirus.

When it comes to fighting COVID-19 and spotting unsupported treatment claims, follow these tips:

Now, share what you know, and ask others to do the same.

View post:
FTC continues to crack down on companies peddling fake COVID treatments and cures - HamletHub

ThermoGenesis : The History of Cell and Gene Therapy – marketscreener.com

Cell and gene therapies are overlapping fields of research and treatments. While both aim to treat and potentially cure diseases, they have slightly differing approaches and have different historical backgrounds. Due to growing interest surrounding this field, the general public still has much to learn and understand about each of these potentially life-saving therapies.

Below, we provide a general overview and brief historical context for each type of therapy.

Cell therapyis the process of replacing damaged or dysfunctional cells with new, healthy ones by transferring live cells into a patient. These can be autologous (also known as self-to-self, using cells from the patient receiving the treatment) or allogeneic (using cells from a donor for the treatment). While this field of treatment has recently begun to expand, some forms of cell therapy like the cancer-treating hematopoietic stem cell transplantation(HSCT) have been in practice for decades.

While many people have heard of bone marrow transplants, few realize that this procedure is a stem cell therapy. While stem cells can be derived from many sources, such as umbilical cord blood and mobilized peripheral blood, bone marrow derived stem cell therapy is the most commonly used today and has been for more than 50 years.

The first transfusion of human bone marrow was given to a patient with aplastic anemia in 1939. After World War II researchers diligently worked to restore bone marrow function in aplasia patients caused by exposure to radiation produced by the atomic bomb. After a decade of work they were able to show, in a mouse model, that aplasia could be overcome by bone marrow treatment.

The first allogeneic HSCT, which led the way to current protocols, was pioneered by E. Donnall Thomas and his team at the Fred Hutchinson Cancer Research Center and reported in the New England Journal of Medicine in 1957. In this study six patients were treated with radiation and chemotherapy and then received intravenous infusion of bone marrow rich stem cells from a normal donor to reestablish the damaged or defective cells. Since then the field has evolved and expanded worldwide. While almost half of HSCT are allogeneic, the majority of HSCT are autologous, the patient's own stem cells are used for treatment, which carries less risk to the patient.

In 1988, scientists discovered that they could derive stem cells from human embryos and grow the cells in a laboratory. These newly derived stem cells, referred to as embryonic stem cells (hESCs), were found to be pluripotent, meaning they can give rise to virtually any other type of cell in the body. This versatility allows hESCs cells to potentially regenerate or repair diseased tissue and organs. Two decades after they were discovered, treatments based on hESCs have been slow in coming because of controversy over their source and concerns that they could turn into tumours once implanted. Only recently, testing has begun as a treatment for two major diseases: heart failure and type 1 diabetes.

In 2006, researchers made a groundbreaking discovery by identifying conditions that would allow some cells to be 'reprogrammed' genetically. This new type of stem cell became known as induced pluripotent stem cells (iPSCs). Since this discovery, the field has expanded tremendously in the past two decades. Stem cell therapies have expanded in use and have been used to treat diseases such as type 1 diabetes, Parkinson's and even spinal cord injuries.

There has also been a growing focus on using other immune cells to treat cancer. Therapies such as CAR T-cellare dependent upon a patient's T-cells, which play a critical role in managing the immune response and killing cells affected by harmful pathogens. These cells are then reengineered to target and kill certain cancerous cells. Several CAR T-cell therapies have been FDA approved, with the first approval being given in 2017 for Yescarta and Kymriah, to be used for the treatment of B-cell leukemia in children and young adults.

Gene therapyis a process that modifies the expression of a gene or alters the biological process of living cells for therapeutic use. This process can take the form of replacing a disease-causing gene with a new, healthy one, inactivating the mutated gene, or introducing a new gene to help the patient's body fight a disease.

While the use of gene therapy to treat humans is fairly new, the science behind it has been used in science for decades. Farmers and geneticists have collaborated for years on crop improvement using cross pollination, genetic engineering and microinjection techniques to create stronger, more resilient crops.

The first human patient to be treated with gene therapy was a four-year old girlsuffering from severe combined immunodeficiencyin 1990. She received treatment for a congenital disease called adenosine deaminase (ADA). Since then, gene therapies have been used to treat diseases such as cancer, cystic fibrosis and hemophilia.In 2017, the FDA gave its first approval of a gene therapy called Luxturna, which is used to treat patients with established genetic vision loss that may result in blindness. Gene therapies are still being studied and developed, with over 1,000 clinical trialscurrently underway.

ThermoGenesis Holdings Inc., is a pioneer and market leader in the development and commercialization of automated cell processing technologies for the cell and gene therapy fields. We market a full suite of solutions for automated clinical biobanking, point-of-care applications and large-scale cell processing and manufacturing with a special emphasis on the emerging CAR-T immunotherapy market. We are committed to making the world a healthier place by creating innovative solutions for those in need.

For more information on the CAR-TXpress multi-system platform, please contact our Sales team.

Disclaimer

Thermogenesis Holdings Inc. published this content on 13 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 April 2021 07:10:03 UTC.

More:
ThermoGenesis : The History of Cell and Gene Therapy - marketscreener.com

Russell Health Honored in Global Business Leaders Magazine’s ’20 Leading Companies of the Year 2021′ – PRNewswire

WILLOWBROOK, Ill., April 14, 2021 /PRNewswire/ --Based in Willowbrook, Illinois, Russell Health is a national marketer and distributor of specialty medical products and services. Russell Health, Inc., was recently awarded as #2 in Global Business Leaders Magazine's "20 Leading Companies of the Year 2021." Based in Atlanta, Georgia, Global Business Leaders Magazine's mission 'focuses on exalting the contribution of leaders who have been the emissary for their respective industries.' Their 2021 Top 20 list features a collection of leaders across industries like medical technology, finance, marketing, blockchain solutions, industrial fabrication, and more. Read more here

Russell Health's full-page feature presents an article titled, "Russell Health: A Mini Amazon for Regenerative Medicine." It discusses the history of Russell Health Inc., ongoing research and benefits of Stem Cell Recruitment Therapy, and well-defined commentary about how Russell Health has redefined the medicine market, even during a global pandemic. Read Russell Health's featured article here

About Russell Health: Russell Health and its partners have distributed regenerative therapy products nationwide and achieved profound clinical outcomes in multiple therapeutic areas including cosmetics, wound care, pain management, podiatry, orthopedic, dentistry and gynecology. With their partners and suppliers, they work to provide innovative life-changing and sustaining products and therapies to patients and healthcare providers around the world.

Russell Health's Stem Cell Recruitment Therapyproducts are intended for homologous use to help repair, reconstruct or supplement the patient's joints or soft tissue as well as help to increase mobility while decreasing pain. These responsibly sourced acellular tissue allografts are helping people of all ages to recover from injuries and get their life back.

Pull Quotes:

"We have built a mini-Amazon for regenerative medicine." (Ryan Salvino, CEO of Russell Health)

"Our ultimate goal from the beginning has been to help people by providing safe alternatives to risky procedures and expensive treatments while offering an alternative to synthetic drugs and embracing more holistic and organic products. We want to continue to become the number one supplier of regenerative medicine in the U.S." (Jonathan Benstent, Vice President of Russell Health)

"While the pandemic caused major disruption throughout the industry, it managed to pivot patients and physicians toward alternative treatments such as Stem Cell Recruitment Therapy. This demand can help in further enhancing the discovery of new applications for Stem Cell Recruitment Therapy products. As a result, Russell Health is working with some of the top leaders in the regenerative medicine field to continue to grow and provide innovative products to customers and their patients." (Global Business Leaders Magazine)

Visit Russell Health online to learn more about Stem Cell Recruitment Therapy. For media inquiries or to contact the Russell Health team directly. Please visit http://www.russellhealth.comor email [emailprotected].

Contact: Veronica Bennett

Address & Phone: 621 Plainfield Rd., Willowbrook, IL 60527; 844-249-6200

Email: [emailprotected]

Online: http://www.russellhealth.com

Social Media: http://www.linkedin.com/company/russell-health:: https://www.facebook.com/russellhealthinc:: https://www.instagram.com/russellhealth:: https://twitter.com/health_russell

Related Files

Ryan Salvino BREAKFILE.pdf

Related Images

russell-health-leading-companies.jpeg Russell Health - Leading Companies Stem Cell Recruitment Therapy

SOURCE Russell Health

Read this article:
Russell Health Honored in Global Business Leaders Magazine's '20 Leading Companies of the Year 2021' - PRNewswire

Durable B-ALL Control With Allogeneic Transplant After CAR T-Cell Therapy – Cancer Therapy Advisor

Children and young adults who underwent an allogeneic hematopoietic stem cell transplant (alloHSCT) after achieving complete response with CD19 CAR T-cell therapy experienced durable B-cell acute lymphoblastic leukemia (B-ALL) control, according to the results of a phase 1 trial (ClinicalTrials.gov Identifier: NCT01593696) published in the Journal of Clinical Oncology.

Although a proportion of patients who undergo CAR T-cell therapy go on to receive alloHSCT, the study authors stated that The role for [alloHSCT] following CD19-CAR T-cell therapy to improve long-term outcomes in [children and young adults] has not been examined.

The phase 1 trial evaluated 50 children and young adults with B-ALL who received CD19.28 CAR T-cell therapy. The primary objective was to determine the maximum tolerated dose of CAR T cells, toxicity, and feasibility of generating CAR T cells in the study population. In addition, this analysis retrospectively evaluated the effect of alloHSCT on survival after CAR T-cell therapy.

At baseline, the median age was 13.5 years (range, 4.3-30.4), and 40 (80%) of the patients were male. The median number of prior regimens was 4 (range, 4.3-30.4); 22 (44%) patients had at least 1 prior HSCT, 2 (4%) had prior CD19-targeted therapy, and 5 (10%) of the patients had prior treatment with blinatumomab.

Complete response was achieved in 31 (62%) of the patients. Among these patients, 28 (90.3%) were negative for minimal residual disease. Higher rates of complete response were associated with primary refractory disease, fewer prior lines of therapy, M1 marrow, or fludarabine/cytarabine-based lymphodepletion. The median overall survival was 10.5 months (95% CI, 6.3-29.2) during a median follow-up of 4.8 years.

Of the 28 patients who achieved complete response, 21 (75%) proceeded to undergo consolidative alloHSCT. The median overall survival for these patients was 70.2 months (95% CI, 10.4-not estimable), with an event-free survival not yet reached. The rate of relapse after alloHSCT was 4.8% (95% CI, 0.3-20.3) at 12 months and 9.5% (95% CI, 1.5-26.8) at 24 months.

Any grade cytokine release syndrome (CRS) developed among 35 (70%) patients, with 9 (18%) experiencing grade 3 to 4 CRS. Of the 10 patients (20%) who developed neurotoxicity, 4 cases were severe. One cardiac arrest occurred during CRS. All patients with CRS, neurotoxicity, and cardiac arrest recovered.

The authors concluded that CD19.28 CAR T cells followed by a consolidative alloHSCT can provide long-term durable disease control in [children and young adults] with relapsed or refractory B-ALL.

Disclosure: Please see the original reference for a full disclosure of authors affiliations.

Reference

Shah NN, Lee DW, Yates B, et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. Published online March 25, 2021. doi:org/10.1200/JCO.20.02262c

See the article here:
Durable B-ALL Control With Allogeneic Transplant After CAR T-Cell Therapy - Cancer Therapy Advisor

CRISPR lauds easy scale-out of cell therapy – BioProcess Insider – BioProcess Insider

The autologous nature of its gene-edited stem cell candidate CTX001 means scaling manufacturing from clinical to commercial will be relatively easy, says CRISPR Therapeutics.

Codeveloped with Vertex Pharmaceuticals, CRISPR Therapeutics CTX001 is an autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy targeting patients suffering from -thalassemia and sickle cell disease.

Production of the candidate involves collecting a patients own blood stem cells via mobilization and apheresis and editing them with CRISPR/Cas9 to increase fetal hemoglobin (HbF) expression. When the edited cells are returned to the patient, they are expected to generate red blood cells that have increased levels of HbF, which may reduce or eliminate patients symptoms.

Image: iStock/zest_marina

The firm recently presented positive Phase I/II data for the autologous candidate and now has an eye on scaling-up production as it progresses through the clinic.

We dont believe we will need to make any major modifications to the manufacturing process that we started with, to take it into commercialization, and thats a huge benefit, Lawrence Klein, CRISPRs COO said at the 20th Annual Needham Virtual Healthcare Conference this week. And thats just by virtue of the fact that our initial manufacturing process led to the type of efficacy that we saw, and we purpose built that process to enable commercial scale.

Therefore, to increase production the firm needs to add more suites: scaling-out, rather then scaling-up.

You can basically just clone those suites, and the more suites you have the more throughput you have, he told delegates. Its not like if youre moving from a 10-liter reactor to a 10,000-liter reactor [when] things change in terms of the biochemistry of the process.

To augment production adding people and facility and instrumentation the firm uses undisclosed contract manufacturing organizations (CMO).

When we started the trial, we had one, said Klein. Weve added CMOs since that point, different facilities and we intend to continue doing that to enable broader scale in different geographies.

The CMOs that weve chosen, theyre scalable. And you can see the major CMOs are making heavy investments in this space of gene and cell therapy. And so, we think well be able to scale that capacity as we move forward into commercialization.

CRISPR Therapeutics is also building a cell therapy manufacturing facility in Framingham, Massachusetts being designed to provide GMP manufacturing in compliance with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulations and guidelines.

Read more:
CRISPR lauds easy scale-out of cell therapy - BioProcess Insider - BioProcess Insider

NeoProgen, Inc. Receives First Granted Patent for Method to Treat Cardiac Conditions using Neonatal Heart-derived Medicinal Signaling Cells (nMSCs)…

BALTIMORE--(BUSINESS WIRE)-- NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other inflammatory diseases, announced that it has received a patent from the United States Patent Office Patent No.: US 10.967,007 B2 Cardiac Stem Cells for Cardiac Repair. The innovation was developed by Dr. Sunjay Kaushal, a pediatric cardiac surgeon, while he was at the University of Maryland, Baltimore and NeoProgen is the exclusive licensee of the newly issued patent.

The patent claims describe methods for treating cardiac conditions with an exosome-based therapy (conditioned media) derived from neonatal cardiac stem cells. The unique approach that the company has taken to isolating the cells, culturing nMSCs, characterizing them by their secretome and exosome production, and improving cardiac function by administering allogeneic nMSCs to adults and children represents an exciting therapy for heart failure and other inflammatory diseases.

As a Cardiovascular-Thoracic surgeon, my goal is to help patients by performing heart transplantations and heart surgeries, in many cases to newborn babies that need these procedures to correct life-threatening congenital problems. For many years I have had the opportunity to study stem cells that are present in the very young heart to treat chronic diseases seen in adults, having been involved as a Principal Investigator in multiple stem cell trials. Comparative studies analyzing multiple stem cell types support the notion that nMSCs and their secretomes/exosomes derived from neonatal heart tissue covered under this patent are the most regenerative stem cell type discovered, said Dr. Sunjay Kaushal, MD, PhD, Division Head Cardiovascular Thoracic Surgery at Ann & Robert H. Lurie Childrens Hospital of Chicago and founder of NeoProgen. Dr. Kaushal explained, Stem cell ingredients are key to their success in clinical trials. nMSCs are very special cells with a great regenerative potential and prolific abilities. The innate abilities of secretomes/exosomes from these cells set us apart from other stem cell types used in clinical trials. Its my hope that in the future pediatric and adult patients will not only benefit from the surgeries but also by stem cell therapies like this one to improve their outcomes and quality of life.

This is a major milestone for NeoProgen, said Bill Niland, the companys CEO who has successfully founded and exited three previous healthcare companies. In addition to expanding our patent portfolio, this patent gives us coverage of our #1 asset: a secretome/exosome product that we expect to get into a phase 1 trial this year for Ischemic Cardiomyopathy, where we have excellent pre-clinical results.

The company has engaged BioPharma Capital to exclusively represent them in actively raising capital and in discussions with potential strategic partners. Dan Ross, Managing Partner of BioPharma Capital added, NeoProgen stands out amongst its peers as harnessing a uniquely potent source for stem cells that, along with this newly issued patent, addresses both of the challenges that have historically beleaguered the stem cell therapy space and continue to do so today: manufacturing/supply and IP. We are pleased to be working with NeoProgen and look forward to doing our small part in helping this promising treatment make its way towards helping patients around the world.

About NeoProgen:

NeoProgen, Inc., is a pre-clinical stage company developing human neonatal heart-derived Medicinal Signaling Cells (nMSCs) and an exosome-based product for tissue repair and regeneration for the treatment of heart failure (HF) and other inflammatory diseases.

About BioPharma Capital:

BioPharma Capital, LLC provides life sciences focused investment banking services, including M&A Advisory, strategic partnering and financing transaction management. We are dedicated to maximizing value for our clients using credible scientific and evidence driven approaches. Our clients are typically pharmaceutical and biotech companies considering partnering, out-licensing, divestitures, fund raising or corporate sales. Our team provides decades of experience in transaction support, healthcare strategy consulting, pricing and market access, forecasting, investment banking and translational research. We understand the science and technology behind the assets we represent and we have vast expertise managing transactions. Securities and Investment Banking Services are offered through Ashland Securities, LLC. Supervised by the Home Office, located at 80 S.W. 8th Street, Suite 2000 Miami, Florida 33130. Phone Number 305-279-3176. Member FINRA SIPC. Please refer to BrokerCheck for more information about Ashland Securities, LLC. BioPharma Capital, LLC and Ashland Securities, LLC are separate and unaffiliated entities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005401/en/

Continued here:
NeoProgen, Inc. Receives First Granted Patent for Method to Treat Cardiac Conditions using Neonatal Heart-derived Medicinal Signaling Cells (nMSCs)...

CRISPR gene therapy for sickle cell disease approved by the FDA – BioNews

12 April 2021

A clinical trial for a new gene therapy approach to treat sickle cell disease has been approved to proceed by the US Food and Drug Administration.

Patients with sickle cell disease have a mutation in the beta-haemoglobin gene, causing them to produce misshapen red blood cells that can block blood vessels leading to severe pain, anaemia and potentially life-threatening complications, such as organ damage and strokes.Currently, the only cureis a stem cell transplant from a healthy donor, but in the newly-approved trial, scientists from the University of California will use CRISPR/Cas9 genome editing to replace the faulty gene with a functional version.

'Gene therapy and genome editing allow each patient to serve as their own stem cell donor,' said Professor Donald Kohn, from the Broad Stem Cell Research Centre at the University of California Los Angeles, one of the clinical trial leaders. 'In theory, these approaches should be much safer than a transplant from another person and could become universally available because they eliminate the need to find the needle in a haystack that is a matched stem cell donor.'

In the trial, blood stem cells will be harvested from the patients and grown in the lab. CRISPR/Cas9 will be used to 'cut and replace' a sequence of DNA containing the mutation with a healthy copy. The edited cells will then be returned to the patient's body in the same way they would be if the patient was receiving donor stem cells.

'The goal of this form of genome editing therapy is to correct the mutation in enough stem cells so the resulting blood in circulation has corrected red blood cells,' said Dr Mark Walters, from the University of California San Francisco Benioff Children's Hospital, another of the clinical trial leaders.

The study will take place over four years, and include six adults and three adolescents with severe sickle cell disease, testing both safety and efficacy.

The treatment does have risks: the patientswill need to have high dose chemotherapy, to kill allremaining bloodstem cells before the modified stem cells are put back. This is also necessary before receiving donor stem cells and can cause severe side effects as the patient's immune system is temporarily disabled.

A similar trial, using CRISPR/Cas9 to activate bone marrow stem cells to produce an alternative version of haemoglobin, rather than correcting the faulty version, has recently shown promising results in a patient with sickle cell disease (see BioNews 1052).

Read more here:
CRISPR gene therapy for sickle cell disease approved by the FDA - BioNews